Flurbiprofen cataplasm and preparation method thereof

A flurbiprofen and solvent technology, which is applied in the field of pharmaceutical preparations, can solve the problems of low solubility of poorly soluble drugs, poor transdermal absorption performance, affecting treatment effects, etc., and achieves improved storage stability, improved transdermal absorption performance, penetration good skin absorption

Active Publication Date: 2021-06-29
GUANGZHOU NEWORLD PHARMA CO LTD
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And the cataplasm contains a large amount of water and glycerin, and the insoluble drug has low solubility in water and glycerin. Crystallization will occur after long-term storage after the preparation of the cataplasm, resulting in poor transdermal absorption of the drug and affecting the therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flurbiprofen cataplasm and preparation method thereof
  • Flurbiprofen cataplasm and preparation method thereof
  • Flurbiprofen cataplasm and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051]The cataplasm of insoluble drugs provided in this embodiment is composed of a backing, a paste and an anti-adhesive film, and the composition of the paste is as follows:

[0052]

[0053]

[0054] The preparation method comprises the following steps:

[0055] Add flurbiprofen to a solution composed of polyethylene glycol-12-hydroxystearate (KolliphorHS 15), Span 83 and crotamiton, mix and stir evenly to obtain component A;

[0056] Dissolve tartaric acid and polyvinyl alcohol in purified water, heat to 85°C, stir evenly until it becomes a transparent colorless liquid, cool down to 35°C, add gelatin and stir evenly until a clear and translucent colloid is obtained to obtain component B;

[0057] Dissolve sodium carboxymethylcellulose in glycerin, add polyethylene glycol, NP-700, micropowder silica gel, disodium edetate and aluminum hydroxide, and stir evenly to obtain component C.

[0058] In the reaction kettle, first add component B, then add component A, and sti...

Embodiment 2

[0061] The insoluble drug cataplasm provided in this embodiment is composed of a backing, a paste and an anti-adhesive film, and the composition of the paste is as follows:

[0062]

[0063] The preparation method is as follows:

[0064] Dissolve flurbiprofen in a solution composed of Span 83, Kolliphor HS 15, N-methylpyrrolidone (NMP) and crotamiton, mix and stir evenly to obtain component A;

[0065] Dissolve tartaric acid and polyvinyl alcohol in purified water, heat to 85°C, stir evenly until it becomes a transparent colorless liquid, cool down to 35°C, add gelatin and stir evenly until a clear and translucent colloid is obtained to obtain component B;

[0066] Dissolve sodium carboxymethylcellulose in glycerin first, then add polyethylene glycol, NP-700, micropowder silica gel, titanium dioxide, disodium edetate and aluminum glycolate, and stir evenly to obtain component C.

[0067] In the reaction kettle, first add component B, then add component A, and stir to make ...

Embodiment 3

[0070] The insoluble drug cataplasm provided in this embodiment is composed of a backing, a paste and an anti-adhesive film, and the composition of the paste is as follows:

[0071]

[0072]

[0073] The preparation method is as follows:

[0074] Dissolve flurbiprofen in a solution composed of KolliphorHS 15, Span 83 and N-methylpyrrolidone (NMP), mix and stir evenly to obtain component A;

[0075] Dissolve tartaric acid and polyvinyl alcohol in purified water, heat to 85°C, stir evenly until it becomes a transparent colorless liquid, cool down to 35°C, add gelatin and stir evenly until a clear and translucent colloid is obtained to obtain component B;

[0076] Dissolve sodium carboxymethylcellulose in glycerin first, then add polyethylene glycol, NP-800, micropowder silica gel, titanium dioxide, disodium edetate and aluminum hydroxide, and stir evenly to obtain component C.

[0077] In the reaction kettle, first add component B, then add component A, and stir to make a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a flurbiprofen cataplasm and a preparation method thereof. The cataplasm consists of a backing, a paste body and an anti-adhesion membrane, wherein the paste body is prepared from the following components: emulsion, a first tackifier, a humectant, a gel skeleton material, a cross-linking agent, a cross-linking regulator and a filler; the emulsion is obtained by mixing a component A and a component B; the component A is obtained by mixing flurbiprofen, a surfactant and a solvent; the component B is prepared from a pH regulator, a second tackifier and water; the surfactant is prepared from benzyl ether and span, or is prepared from Kolliphor HS 15 and span; and the gel skeleton material is selected from at least one of partially neutralized sodium polyacrylate, carbomer, polyacrylic acid, polyvinylpyrrolidone and polybutylene. The flurbiprofen cataplasm is good in percutaneous absorption and good in storage stability, and drug crystals cannot be separated out after long-term storage.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a flurbiprofen cataplasm and a preparation method thereof. Background technique [0002] Insoluble drugs are one of the typical non-steroidal anti-inflammatory drugs (NSAIDs), which mainly produce anti-inflammatory, analgesic and anti-inflammatory effects by inhibiting the synthesis of prostaglandins (PG) in the body. It is widely used clinically for the relief of osteoarthritis, rheumatoid arthritis, and various pain symptoms. [0003] Oral administration of non-steroidal anti-inflammatory drugs has the disadvantages of low drug availability, short duration of drug efficacy, frequent administration of "peaks and valleys" in blood concentration, and large gastrointestinal and systemic side effects. In order to reduce the side effects produced by NSAIDs, external application of NSAIDs has become the first choice for patients clinically. [0004] Catalyst is a new type ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/192A61K47/14A61K47/22A61P29/00A61P19/02
CPCA61K9/7023A61K31/192A61K47/14A61K47/22A61P29/00A61P19/02
Inventor 吴传斌陈航平刘晨红冯汝鹏李峰温新国张敏敏
Owner GUANGZHOU NEWORLD PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap